trial summary · NCT07878988
This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors
A Phase 1/1b, Muticenter Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors
Trial record from the TrialBase DB dataset, status RECRUITING, condition Colorectal Cancer, sponsored by LTZ Therapeutics, Inc.. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This is a first-in-human, Phase 1, multi-center, open-label study to characterize the safety, pharmacokinetics, pharmacodynamics, and preliminary anti tumor activity of LTZ-232 as monotherapy in adult participants with unresectable or metastatic colorectal cancer and other solid tumors failing standard therapies.
Source record: https://clinicaltrials.gov/study/NCT07878988
Facts
| registry id | NCT07878988 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Colorectal Cancer |
| sponsor | LTZ Therapeutics, Inc. |
| sponsor class | INDUSTRY |
| enrollment | 152 |
| start date | 2026-12 |
| primary completion | 2031-12 |
| completion | 2031-12 |
| results posted | not reported |
Conditions
- Colorectal Cancer
- Advanced/Metastatic Solid Tumor
- Solid Tumor (Phase I)
- EPCAM
- Colon Cancer
Interventions
- LTZ-232
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.